Docket No.

281259US0PCT

## IAP20 Rec'd PCT/FTO 17 JAN 2006

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Angelo GUGLIELMOTTI, et al.

SERIAL NO: New U.S. PCT Application Based on PCT/EP04/07635

GAU:

FILED:

Herewith

**EXAMINER:** 

FOR:

USE OF INDAZOLE DERIVATIVES FOR THE TREATMENT OF NEUROPATHIC PAIN

#### INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

#### REFERENCES

The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed
references are attached, where required, as are either statements of relevancy or any readily available English
translations of pertinent portions of any non-English language references.

A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

#### RELATED CASES

Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be
related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies
of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the
attached PTO form 1449.

☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

#### CERTIFICATION

Each item of information contained in this information disclosure statement was first cited in any communication
from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of
this statement.

☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

#### DEPOSIT ACCOUNT

Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

Norman F. Oblon

Registration No. 24,618

Customer Number

Tel. (703) 413-3000 Fax. (703) 413-2220 (OSMMN 05/03)

Surinder Sachar

Registration No. 34,423

# IAP20 Rac'd PCT/770 17 JAN 2006 SHEET 1 OF 1

Form PTO 1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE				ATTY DOCKET NO. 281259US0PCT		SERIAINO 6 1854 New U.S. PCT Application		
				Based on PC1/EP04/0/635				
LIST OF	REFE	RENCES CITED BY AF	PLICANT	APPLICANT Angelo GUGLIELMOTTI, et al.				
				FILING DATE GROUP				
				Herewith				
		· · · · · · · · · · · · · · · · · · ·		U.S. PATENT DOCUMENTS		I		
EXAMINER		DOCUMENT	DATE	NAME	CLASS	SUB	FILING DATE	
INITIAL		NUMBER	-  - <del></del>		OBAGO	CLASS	IF APPROPRIATE	
	AA	5,817,676	10/6/98	CATLOW, John T. et al.	<del></del>	-		
	AB							
	AC							
<u> </u>	AD AE							
,	AE	<u> </u>	<u> </u>	DEICH DATENT DOCUMENTS	L	LI		
			T FO	REIGN PATENT DOCUMENTS				
		DOCUMENT NUMBER	DATE	COUNTRY			TRANSLATION	
	AF	0 975 623	2/2/00	EP		YES	S NO No	
	AG	93/03725	3/4/93	wo .			No	
	AH	2004/014922	2/19/04	wo			No	
	Al	2004/014022	2 10/04					
	AJ							
		OTHER R	FEERENCES (	Including Author, Title, Date, Pertinent	Pages e	tc )		
							Multiple Peripheral 5	
	AJ	DOAK, G.J.; SAWYNOK, J.: "Formalin-Induced Nociceptive Behavior and Edema: Involvement of Multiple Peripheral 5- Hydroxytryptamine Receptor Subtypes" NEUROSCIENCE, Vol. 80, No. 3, 1997, Pages 939-949, XP002279566						
	AK	DONAHUE, et al.: "Electrolytic Lesion of the Anterior Cingulate Cortex Decreases Inflammatory, but not Neuropathic Nociceptive Behavior in Rats" BRAIN RESEARCH, Vol. 897, No. 1-2, 2001, Pages 131-138, XP002279567						
	AL	BEERS, M. and BERKOW, R.: "The Merck Manual of Diagnosis and Therapy, Seventeenth Edition" 1999, MERCK RESEARCH LABORATORIES, WHITEHOUSE STATION, N.J., XP002279568, Page 1371-1372						
	АМ	ESPEJOE, et al.: "Antagonism of Peripheral 5-HT4 Receptors Reduces Visceral and Cutaneous Pain in Mice, and Induces Visceral Analgsia After Simultaneous Inactivation f 5-HT3 Receptors" BRAIN RESEARCH, Amsterdam, NL; Vol. 788, No.						
	A N 1	1/2, 1998, Pages 20-2 TORSSELL, Kurt et a		ructure and Synthesis of Alkaloids From	/aleriana (	Officinalis L	", Acta Chemica	
	AN	Scandinavica 21 (1), I		967 ter S.: "Management of Chronic Pain", TI	IE LANCE	T V-L 25	Dece 1865 60 1000	
	AO	ASHBURN, Michael A	., STAATS, PE	ter 5.: Management of Chronic Pain , 11	TE LANCE	: I , VOI. 353	5, Pages 1005-09, 1999	
	AP	BANNON, A.W., et al.: "ABT-594, a novel cholinergic channel modulator, is efficacious in nerve ligation and diabetic neuropathy models of neuropathic pain", BRAIN RESEARCH, Vol. 801, Pages 158-63, 1998						
	AQ	BENNETT, Gary J. ar Those Seen in Man",		A Peripheral Mononeuropathy in Rat that is 87-107, 1988	Produces	Disorders o	of Pain Sensation Like	
	AR COURTEIX, C., ESCHALIER, A., and LAVARENNE, J.: "Streptozocin-Induced Diabetic Rats: Behavioural Evidence for a Model of Chronic Pain", PAIN, 53, Pages 81-88, 1993							
	AS	SCHOLZ Land WOOLE C. L. "Can We Conquer Pain?" NATURE NEUROSCIENCE Volume 5, Pages 1062-1067						
	AT SELTZER, Z. et al.: "A Novel Behavioral Model of Neuropathic Pain Disorders Produced in Rats by Partial Sciatic Nerve Injury", PAIN, 43, Pages 205-218, 1990						y Partial Sciatic Nerve	
	AU WOOLF, Clifford J. et al.: "Neuropathic Pain: Aetiology, Symptoms, Mechanisms, and Management", THE LANCET, Vol. 353, Pages 1959-1964, June 5, 1999						nt", THE LANCET, Vol.	
	AV				Addi	tional Refe	rences sheet(s) attached	
Examiner		<u> </u>			Date Cor	nsidered		
*Examiner: Ir	nitial if r	eference is considered	, whether or no	citation is in conformance with MPEP 60	l )9; Draw lii	ne through	citation if not in	
conformance	and no	ot considered. Include o	opy of this form	with next communication to applicant.		_		

New U.S. PCT Application based on PCT/EP04/07635 Docket No. 281259US0PCT

#### STATEMENT OF RELEVANCY

•	AH and AJ-AM have been cited in the International Search es are being submitted herewith only when not automatically rching Authority.
	have been cited in the correspondingeferences is being submitted herewith.
3) References <u>AN-AU</u> a is being submitted herewith.	are discussed in the specification. A copy of these references
4) Referencescopy of these references is being	are additional prior art known to Applicant. A submitted herewith.